A comparison of three doses of omeprazole in the treatment of equine gastric ulcer syndrome: A blinded, randomised, dose response clinical trial
|
|
- Norma Hilary Lyons
- 5 years ago
- Views:
Transcription
1 Equine Veterinary Journal ISSN DOI: /evj A comparison of three doses of omeprazole in the treatment of equine gastric ulcer syndrome: A blinded, randomised, dose response clinical trial B. W. SYKES*, K. M. SYKES and G. D. HALLOWELL BW Sykes Consultancy, Upper Orara, New South Wales, Australia School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington, UK. *Correspondence bensykes21@hotmail.com; Received: ; Accepted: Summary Reasons for performing the study: A previous study demonstrated that a dose effect between 1.6 and 4. mg/kg bwt of omeprazole per os s.i.d. is present in the treatment of equine gastric ulceration. In the same study, healing of glandular ulceration appeared inferior to healing of squamous ulceration. However, several limitations were recognised in that study and further investigation is warranted. Objectives: To further investigate the presence of a dose relationship in the treatment of gastric ulceration under conditions that may favour omeprazole efficacy such as administration prior to exercise and after a brief fast, and potential differences between the response of squamous and glandular ulceration to omeprazole therapy. Study design: A blinded, randomised, dose response clinical trial. Methods: Sixty Thoroughbred racehorses with grade 2/4 squamous and/or glandular ulceration were identified by gastroscopy. Horses were randomly assigned to receive either 1., 2. or 4. mg/kg bwt of enteric coated omeprazole per os s.i.d. 1 4 h prior to exercise. Gastroscopy was repeated at approximately 28 days. Results: The lower doses studied (1. and 2. mg/kg bwt) were noninferior to the reference dose (4. mg/kg bwt) in the treatment of squamous ulceration. Healing was greater in squamous ulceration than glandular ulceration (86% vs. 14%; P<.1). Improvement in ulcer grade was more likely in squamous lesions than glandular lesions (96% vs. 34%; P<.1). Worsening of the glandular ulcer grade was observed in 36% of horses. Conclusions: The results of this study suggest that, under the conditions studied, where omeprazole is administered before exercise and following a brief fast, doses of omeprazole as low as 1 mg/kg bwt per os s.i.d. may be as effective as higher doses. The proportion of glandular ulceration that heals with 28 days of omeprazole therapy is less than that of squamous ulceration. Keywords: horse; proton-pump inhibitor; squamous; glandular; gastric; ulcer Introduction Omeprazole is widely used in the treatment of equine gastric ulcer syndrome (EGUS) [1 5]. A previous study found a significant dose response in clinical patients with a dose of bwt per os s.i.d. resulting in a higher proportion of healed ulcers than a 1.6 mg/kg bwt per os s.i.d. dose [6]. However, 2 key factors, namely timing and the potential effect of fasting, may have resulted in suboptimal efficacy of omeprazole in that study. While it is widely believed that once daily dosing of omeprazole results in 24 h of acid suppression [7], and this is supported by experimental studies [8 14], a study by Merritt et al. [15] suggested that the duration of acid suppression may be <12 h. In the previous dose response study, omeprazole was administered approximately 2 h before exercise [6]. Given that exercise is thought to be the period during which damage to the squamous mucosa is most likely to occur [16], the long duration between administration and exercise may have reduced the efficacy of omeprazole at the doses studied. Furthermore, fasting may improve the bioavailability of omeprazole by as much as 3% [11]. The current authors have observed in the local racehorse population that most of the horses consume their evening meal within 4 h of feeding and propose that gastric fill is likely to be minimal if omeprazole is administered prior to exercise, which may favour absorption of omeprazole. Taking into account these 2 factors, administration of omeprazole closer to the high-risk period associated with exercise may result in enhanced efficacy across a range of doses. While the term EGUS is widely used to describe equine gastric ulceration, an attempt has recently been made to clarify the use of the terminology [17]. The term EGUS is all encompassing for ulcerative diseases of the stomach and within that broad definition more specific disease conditions or syndromes exist. The best understood of these is equine squamous gastric ulcer syndrome (ESGUS) for which the prevalence, risk factors and treatment are well described [1 5,18 23]. Equine glandular gastric ulcer syndrome (EGGUS) is less well recognised but recent studies have demonstrated a high prevalence in certain populations [18,2,24,25]. While glandular ulceration may result in delayed gastric emptying and secondary squamous ulceration in individual animals, it has been reported that the prevalence of squamous and glandular ulceration within populations are unrelated to each other [18,2,25] suggesting that within the general population that the majority of squamous ulceration is primary in origin. The proposed pathophysiology of EGGUS differs from that of ESGUS [7]. Consistent with this, a previous study [6] suggested that the response of EGGUS to omeprazole therapy is inferior compared with the response of ESGUS and the effect observed warrants further investigation. The null hypotheses for this study are that there will be an equal healing response between ESGUS and EGGUS to omeprazole and that there will be a >2% difference in response to omeprazole therapy between the reference dose ( bwt) and the 2 lower doses (1 and bwt). Materials and methods Recruitment and examination Thoroughbred horses from 5 stables were examined during June 212. Prior to examination all horses were fed their normal evening feed, but any remaining food was removed 6 8 h prior to endoscopy. Water was not withheld and horses exercised normally on the morning of the examination at the trainers discretion. Horses were sedated with detomidine (1 2 μg Dozadine/kg bwt i.v.) a and examined using a 3 m flexible videoendoscope (Portascope) b. The squamous and glandular mucosa were scored by a single investigator (B.W.S.) using a 4 point scale as described by the EGUS Council [26]. Based on the results of the gastroscopic examination, horses that met the inclusion criteria were enrolled into the study. Inclusion criteria for the study were horses with grade 2 or greater ulceration of the squamous and/or glandular mucosa, in race training and expected to remain in work Equine Veterinary Journal 47 (215) EVJ Ltd 285
2 Comparison of 3 doses of omeprazole in EGUS treatment B. W. Sykes et al. for the next 4 weeks, not receiving any medical treatment for EGUS and otherwise considered to be free of other significant disease. Group allocation and blinding Once enrolled into the study, horses were stratified by trainer and randomly allocated to a dose group by pulling their names out of a hat. Horses were stratified by trainer to reduce the variability in the diet and management of the horses as these have been shown to be risk factors for ulcer development [24]. One investigator (K.M.S.) was responsible for randomisation while the remaining investigators remained blinded to the group allocation until scoring was completed and recorded. The trainers were not blinded to the treatment group. The study protocol allowed for randomisation to be broken in the event of an adverse event. Treatment protocols Horses were fed and exercised at the trainers discretion determined by their normal routine, housed in individual stalls, bedded on wood shavings and fed a diet typical of Australian racehorses [27]. All horses were fed twice daily, with the morning feed within 2 h of completing exercise, and the afternoon feed approximately h before exercising. A commercially available, enteric coated omeprazole paste formulation (Gastrozol) a was administered per os 1 4 h prior to exercise each morning at a dose of 5, 1 or 2 mg. This is equivalent to 1, 2 and bwt, respectively, for a 5 kg horse. To comply with the local regulations for racing, where, in addition to the requirement for the observation of withdrawal times, the administration of all pharmaceuticals is prohibited on the day of racing, omeprazole was not administered on the day of racing. Follow-up endoscopy Repeat gastroscopy, as described above, was scheduled between Days 25 and 3. Some variation was allowed in the timing of the repeat gastroscopic examination to accommodate for the individual horses racing schedules. The squamous and glandular mucosa were scored and assessed separately for each horse. Where the starting grade was 2 for the particular mucosa, ulcer healing was defined as change to grade 1 [6]. Where a starting ulcer grade of 2 was present in the particular mucosa, horses were considered to have improved if the ulcer score for the region decreased by at least one grade. Where the starting score, for either the squamous or glandular mucosa, was 2 and subsequently changed to 1 the horse was considered to have both healed and improved for that mucosa [1]. Horses with a submaximal starting ulcer grade (<4) for the squamous or glandular mucosa were considered to have worsened if their ulcer grade for that particular mucosa increased by at least one grade. Data analysis Data for time to follow-up, age and weight were assessed using a Shapiro Wilk test and were normally distributed with the groups compared using analysis of variance (ANOVA). The rest of the data were not normally distributed. Wilcoxon paired test was used to assess changes in ulcer scores within groups over time. A Chi-squared test was used to evaluate differences in sex between the groups. Either a Chi-squared (if 8% of the groups have a frequency 5) or a Fisher s exact test (when <8% of the groups have a frequency of 5 or greater) was used to evaluate healing, improvement and worsening of ulcers between groups, the effect of sex on ulcer healing, improvement or worsening and differences between glandular and squamous ulcer responses for each dose and overall. A Kruskal Wallis test was used to evaluate any differences in the numbers of race starts between treatment groups and any differences in the change in ulcer score over time between groups. Noninferiority was assessed using the upper limit of the 9% confidence interval of the differences in failure rate of the lower doses (1 and bwt) vs. the reference dose ( bwt). The confidence intervals to test for noninferiority were calculated using Wilson s method. Treatment effects were considered significantly different (i.e. noninferiority could not be demonstrated) if the upper limit of the 9% confidence interval (CI) exceeded 2%. An a priori noninferiority margin of 2% is commonly used when studies of this nature have not previously been published in the literature [28] and a recent, similar study evaluating placebo vs. misoprostol for the prevention of nonsteroidal anti-inflammatory drug (NSAID)-associated gastrointestinal injury in healthy human volunteers similarly set the a priori noninferiority margin at 17% [29]. Data are presented as mean ± s.d. and 95% CI where appropriate for continuous data and as median and interquartile ranges (IQR) for non-normally distributed data. Odds ratios (OR) and 95% CIs are displayed for binomial data. Commercially available statistical software packages were used (GraphPad 4. c, SPSS for Windows 15. d ). The 95% CIs are displayed using Jeffrey s intervals and calculated using online statistical software e. Noninferiority statistics were performed using online statistical software (Winpepi Compare 2 3.8) f. Significance was determined at P<.5. Results Horses Seventy-four horses were examined with 6 horses aged 2 7 years meeting the inclusion criteria. Three horses were lost to follow-up from both the 2 and bwt groups after being retired by the trainer for unrelated reasons and were excluded from data analysis. No difference in age was noted between groups (P =.4). Mean (± s.d.) weight was not significantly different between the groups (1 mg/kg bwt 52 ± 27 kg; bwt 512 ± 49 kg; bwt 58 ± 41 kg; P =.7). The distribution of female:male horses was not different between groups (1 mg/kg bwt 11:9; bwt 4:13; bwt 7:1; P =.2). There was no effect of sex on: ulcer healing (squamous male 87% [95% CI = 72 96], female 84% [95% CI = 64 95, P>.9]; glandular male 19% [95% CI = 7 39], female 7% [95% CI = 1 29, P =.6]); improvement (squamous male 94% [95% CI = 81 99], female 1% [95% CI = 88 1, P =.5]; glandular male 38% [95% CI = 2 59], female 29% [95% CI = 11 55, P =.7]); or glandular ulcer worsening (male 41% [95% CI = 24 59], female 29% [95% CI = 12 53, P =.5]). The horses had been in work for between 2 weeks and 12 months, although data were not specifically collected for analysis between groups, and, with the exception of the 6 horses described above, all horses remained in work without significant alteration in their standard routine. No adverse events were noted and blinding was maintained throughout the study. Gastroscopy The entire squamous mucosa was adequately observed in all examinations. Due to incomplete emptying of the stomach, the glandular mucosa was inadequately observed at enrolment in 5 horses and at follow-up in 3, 3 and 2 horses in the 1, 2 and bwt groups, respectively. In the remaining horses, residual fluid in the stomach obscured observation of the most ventral portion of the glandular body; however, the majority of the glandular body and entire pyloric antrum was visible. Where only the squamous mucosa was observed at enrolment, the horse was still considered eligible for inclusion with only the squamous mucosal score considered for statistical analysis. For horses where the glandular mucosa was not adequately observed at follow-up, the pre- and post treatment glandular mucosal scores were excluded from data analysis while the squamous scores were retained. Allowing for horses lost to follow-up and failure to observe the glandular mucosa on all occasions, the squamous mucosa was observed on both occasions in 2, 17 and 17 horses in the 1, 2 and bwt groups, respectively. The glandular mucosa was adequately observed on both occasions in 17, 14 and 15 horses in the 1, 2 and bwt groups, respectively. Days to follow-up and number of race starts Time to follow-up examination, 27.5 ± 1.5, 27.8 ± 1.4 and 27.9 ± 1.6 days in the 1, 2 and bwt groups, respectively, was not different between the groups (P =.7). The number of race starts for the 1 mg/kg bwt (; IQR: 2), bwt (1; IQR: 3) and bwt (1; IQR: 2) groups were not different between groups (P =.5). 286 Equine Veterinary Journal 47 (215) EVJ Ltd
3 B. W. Sykes et al. Comparison of 3 doses of omeprazole in EGUS treatment Number of horses mg/kg 4. mg/kg 2. mg/kg 4. mg/kg Grade Ulcer scores Squamous mucosa Glandular mucosa Grade /1 Grade 2 Grade 3 Grade 4 Fig 1: Distribution of equine squamous gastric ulcer syndrome and equine glandular gastric ulcer syndrome scores between the groups at enrolment. The overall prevalence of grade 2 or greater ulceration was 8% for the squamous mucosa and, in the horses where the glandular mucosa was adequately observed at enrolment, 65% for the glandular mucosa. The distribution of pretreatment squamous and glandular ulcer scores of horses included in the final data analysis are displayed in Figure 1. Squamous ulcer scores pre- and post treatment are displayed in Figure 2. No difference between the doses was observed in the change in squamous ulcer score (P =.8). Glandular ulcer scores pre- and post treatment are displayed in Figure 3. No difference between the doses was observed in the change in glandular ulcer score (P>.9). The improvement and healing response rates of the squamous and glandular ulceration are shown in Table 1. In the squamous mucosa no differences between doses were observed for either improvement (4 vs. bwt; OR =.18 [95% CI = ] and 4 vs. 1 mg/kg bwt; OR =.16 [95% CI = ]; P =.3) or healing (4 vs. bwt; OR =.38 [95% CI =.6 2.4] and 4 vs. 1 mg/kg bwt; OR =.2 [95% CI =.2 2.3]; P =.4). Similarly, in the glandular mucosa no differences between doses were observed for improvement (4 vs. bwt; OR =.45 [95% CI = ] and 4 vs. 1 mg/kg bwt; OR =.84 [95% CI = ]; P =.9), healing (4 vs. bwt; OR = 1. [95% CI = ) and 4 vs. 1 mg/kg bwt; OR =.33 [95% CI = ]; P =.5) or worsening (4 vs. bwt; OR =.53 [95% CI = ] and 4 vs. 1 mg/kg bwt; OR =.67 [95% Grade Fig 3: Box and whisker plot demonstrating median (solid line), interquartile ranges (represented by outer edges of box) and ranges (error bars) before and after treatment for equine glandular gastric ulcer syndrome grades when omeprazole was administered at 1, 2 and bwt per os s.i.d. No difference between the doses was observed (P>.9). CI = ]; P =.4). The success and failure rates for healing and improvement are shown in Figures 4 and 5, respectively. Comparisons between the failure rates of the lower doses (1 and bwt) and the reference dose ( bwt), and the 9% CIs used for the determination of noninferiority are shown in Table 2. Against expectations, the lower doses were more effective than the higher dose; this was more consistent for squamous healing and improvement when compared with glandular healing and improvement (Figs 4, 5). Examination of the confidence interval around the point estimate of the difference in failure rate between 2 treatments provides an indication of whether the novel treatment (lower doses 1or2mg/kg bwt) are noninferior to the reference treatment (higher doses bwt). The a priori difference in failure rate that would be interpreted as clinically significant was set at 2%. As such, if the upper limit of the 9% CI for the difference in failure rate was less than 2% the novel treatment (lowerdose 1or2mg/kg bwt) would be considered noninferior to the reference treatment (high dose bwt). For example, in comparing the results achieved with the 1 and bwt doses with respect to squamous healing; there were fewer failures in the novel (1 mg/kg bwt) treatment when compared with the reference treatment ( bwt) and the point estimate of the difference in failure rate was -19%. The 9% CI of the difference in failure percentage was -4 to 3%. As the upper limit of the 9% CI was less than the a priori of 2% this suggests that the lower dose (1 mg/kg bwt) was noninferior to the reference dose ( bwt) for the healing of squamous ulceration. Noninferiority was similarly demonstrated for the bwt dose with regards to squamous healing and for both the 1 and bwt doses with regards to squamous improvement. Noninferiority was also demonstrated for the 1 and bwt doses with regards to glandular healing and improvement, respectively. Noninferiority could not be demonstrated for the 1 dose and bwt doses with regards to glandular improvement and healing respectively. 1 Fig 2: Box and whisker plot demonstrating median (solid line), interquartile ranges (represented by outer edges of box) and ranges (error bars) before and after treatment for equine squamous gastric ulcer syndrome grades when omeprazole was administered at 1, 2 and bwt per os s.i.d. No difference between the doses was observed (P =.8). Discussion When compared to the reference dose of bwt, noninferiority for the treatment of ESGUS was demonstrated for doses of 1 and bwt. The results for EGGUS were less consistent within noninferiority demonstrated in only 2 of the 4 parameters assessed. However, in the remaining parameters of EGGUS healing, where noninferiority could not be demonstrated, the lower doses had an equivalent or lower failure rate and the one-sided upper limit of the 9% CI approached the 2% a priori margin that was defined as significant. These findings suggest that, under specific conditions, doses as low as 1 mg/kg bwt may be as efficacious as a dose of bwt in the treatment of ESGUS. Further, they suggest that a similar Equine Veterinary Journal 47 (215) EVJ Ltd 287
4 Comparison of 3 doses of omeprazole in EGUS treatment B. W. Sykes et al. TABLE 1: The treatment response of squamous and glandular ulceration to 3 doses of omeprazole Squamous Glandular Response 95% Confidence interval Response 95% Confidence interval Squamous vs. glandular P value Healing (horses with an ulcer score grade 2 at enrolment) Improvement (horses with an ulcer score grade 2 at enrolment) Worsening (horses with an ulcer score < grade 4 at enrolment) Overall 86% (43/5) 74 94% 14% (5/35) 6 29% <.1 bwt 89% (16/18) 69 98% 23% (3/13) 7 5%.5 2. mg/kg bwt 94% (15/16) 74 99% 9% (1/11) 1 35% <.1 4. mg/kg bwt 75% (12/16) 51 91% 9% (1/11) 1 35%.1 Difference between doses Pvalue Overall 96% (48/5) 88 99% 34% (12/35) 2 51% <.1 bwt 1% (18/18) 87 1% 31% (4/13) 11 58% <.1 2. mg/kg bwt 1% (16/16) 86 1% 45% (5/11) 2 73%.2 4. mg/kg bwt 88% (14/16) 66 97% 27% (3/11) 8 57%.3 Difference between doses Pvalue Overall n.a. 36% (16/44) 23 51% n.a. bwt n.a. 38% (6/16) 17 62% n.a. 2. mg/kg bwt n.a. 43% (6/14) 2 68% n.a. 4. mg/kg bwt n.a. 29% (4/14) 11 55% n.a. Difference between doses Pvalue n.a..73 % mg/kg Squamous 1 mg/kg Glandular Success Failure Fig 4: Success and failure rates for healing of equine squamous gastric ulcer syndrome and equine glandular gastric ulcer syndrome when omeprazole was administered at 1, 2 and bwt per os s.i.d. No difference between the doses was observed for healing of either equine squamous gastric ulcer syndrome (P =.28) or equine glandular gastric ulcer syndrome (P =.52). % mg/kg Squamous 1 mg/kg Glandular Success Failure Fig 5: Success and failure rates for improvement of equine squamous gastric ulcer syndrome and equine glandular gastric ulcer syndrome grade when omeprazole was administered at 1, 2 and bwt per os s.i.d. No difference between the doses was observed for improvement of ulcer grade for either equine squamous gastric ulcer syndrome (P =.11) or equine glandular gastric ulcer syndrome (P =.63). effect may be observed in the treatment of EGGUS. Thus, the current findings suggest that the previously observed dose response [6] may not persist under conditions that favour omeprazole efficacy, such as administration prior to exercise and after a brief fast. Given the small number of animals studied and the wide 95% CIs for the data, indicating that the current results are imprecise, further work investigating the use of lower doses in a larger population of horses is warranted. The results clearly demonstrate significant differences between the healing response of ESGUS and EGGUS to omeprazole therapy. Following oral administration of omeprazole maximal serum concentrations occur between 45 and 9 min [11] with effective acid suppression achieved within 1 2 h [15]. The timing of administration in this study, 1 4 h before exercise was intended such that acid suppression would occur immediately prior to high-intensity exercise during which the majority of damage to the squamous mucosa is thought to occur [16]. In man, the inhibition of acid production for at least 2 h each day is recognised as a prerequisite factor for ulcer healing [3]. However, the duration of acid suppression required for ulcer healing in the horse has not been determined. High healing rates have been reported at a dose of bwt per os s.i.d. [1 6], yet in a recent study gastric ph remained >4. for <12 h at that dose [15], suggesting that the duration of acid suppression required for ESGUS healing in the horse differs from that required for healing of gastric ulceration in man. Another potential explanation for the efficacy of the low doses is the effect of fasting on bioavailability. While the horses in this study were not specifically fasted, as a population they consumed a high grain/low roughage diet typical of Australian racehorses [27]. The horses in this study were typically fed h before morning exercise and the authors have observed that the majority consume their meals within 4 h resulting in an effective fasting period of around 8 1 h each day prior to administration of omeprazole the following morning. It is possible that this may have resulted in greater bioavailability of omeprazole. However, this was not specifically investigated in this study and warrants further investigation before any definitive conclusions can be drawn. The last potentially important factor for the differences observed between this and the previous dose response study [6] is the formulation of omeprazole used. Most commercially available omeprazole products, including Gastrogard TM and the preparation used in the previous dose response study, utilise a highly alkaline medium in which the omeprazole is suspended to buffer against gastric acidity [15]. However, the formulation used in the current study utilises enteric coated granules to protect the omeprazole. Direct comparison of the preparations is difficult because no published pharmacokinetic studies, or clinical trials comparing different products exist and caution should be exercised in 288 Equine Veterinary Journal 47 (215) EVJ Ltd
5 B. W. Sykes et al. Comparison of 3 doses of omeprazole in EGUS treatment TABLE 2: Noninferiority analysis of treatment failures when the lower doses (1 and bwt) were compared with the reference dose ( bwt). The lower doses treatment failure were noninferior to the reference dose treatment failure rate as the upper 9% CI (confidence interval) of the percentage difference was less than the 2% a priori margin Failure rates 1 mg/kg bwt bwt bwt Difference in failure (%) Novel treatment failure % minus control ( bwt) treatment failure % Upper and lower 9% confidence interval Squamous healing 6% (1/16) 25% (4/16) -19% -4 to 3% 11% (2/18) 25% (4/16) -14% -36 to 8% Squamous improvement % (/16) 12% (2/16) -12% -32 to 4% % (/18) 12% (2/16) -12% -32 to 3% Glandular healing 91% (1/11) 91% (1/11) % -24 to 24% 77% (1/13) 91% (1/11) -14% -38 to 13% Glandular improvement 55% (6/11) 73% (8/11) -18% -46 to 15% 69% (9/13) 73% (8/11) -4% -31 to 26% applying the results of this study to different formulations of omeprazole. Further work comparing the bioavailability and efficacy of different formulations is justified. The results of this study clearly demonstrate that the healing response of EGGUS to acid suppression therapy with omeprazole is less than that of ESGUS. In man, similar durations of acid suppression are required for healing of the reflux oesophagitis (analogous to squamous ulceration) and ulcerative gastritis (analogous to glandular ulceration) [3], but whether this is the case in the horse is not known. Accurate determination of the duration of acid suppression achieved following omeprazole administration under clinical conditions is required before specific conclusions relating to the duration of acid suppression required for healing of squamous and glandular ulceration in the horse can be made. An alternative explanation is that bacteria may play a role in the development or perpetuation of glandular ulceration and that acid suppression therapy alone may be inadequate. To date there remains significant conflict in the literature as to the role of bacteria in EGGUS. A recent study demonstrated that both gastric-adapted bacteria and opportunistic pathogens may play a role in squamous ulceration [31] but whether the situation is similar in the glandular mucosa is unknown. Helicobacter-like organisms have been identified in horses affected with EGGUS in some studies [32 34] whereas other studies have failed to identify such organisms [35,36] and to date no definitive role for bacteria in the development or perpetuation of glandular ulceration has been established. Antimicrobial therapy is commonly recommended as an adjunct to acid suppression therapy in refractory EGGUS [7,37] and, given the poor response of EGGUS to omeprazole therapy alone, studies evaluating whether antimicrobials improve the response rate are warranted. The potential for NSAIDs to cause EGGUS under clinical conditions is controversial and whether their use may have contributed to the worsening of EGGUS observed in the present study warrants consideration. An ulcerogenic capacity has been demonstrated for flunixin, phenylbutazone and ketoprofen at doses only 5% higher than typically recommended [38] while, at clinical recommended doses phenylbutazone and suxibuzone did not induce gastric ulceration when administered for 15 days [39]. Data regarding the use of NSAIDs was not recorded during the present study and this is a weakness of the study. However, the administration of NSAIDs was not identified as a risk factor for EGGUS in a recent study in Thoroughbred racehorses [24] and the authors have observed that few, if any horses, in the treatment population regularly receive such medications. Regardless, data specifically documenting the use of NSAIDs should be included in future study protocols investigating the therapeutic response of EGGUS to investigate any potential ulcer-generative effect. Data regarding time in work were also not recorded during the present study and is another potential weakness. While time in work has been identified as a risk factor for ESGUS in one study [24] it was, in contrast, not recognised as a risk factor for EGGUS in the same study. Further, time in work has not been demonstrated to be a factor in ulcer healing and as such, the omission of these specific data is unlikely to have influence the outcome of the present study. In conclusion, the results of this study suggest that, under the conditions studied, where omeprazole is administered before exercise and following a brief fast, doses as low as 1 mg/kg bwt per os once daily of the formulation given may be as efficacious as higher doses. However, due to the wide CIs, further studies are needed before definitive conclusions can be drawn. The study clearly demonstrates that the response to omeprazole of EGGUS is inferior to ESGUS and a greater understanding of the efficacy of omeprazole under clinical conditions is needed. Lastly, given the poor response of EGGUS to monotherapy with omeprazole, the evaluation of adjunctive treatments such as antimicrobials is warranted. Authors declaration of interests No competing interests have been declared. Ethical animal research This study was performed in accordance with the New South Wales Department of Primary Industries guidelines for clinical studies and the New South Wales Research Act of Informed consent from the owner, or the trainer acting as an agent for the owner, was obtained at the time of enrolment to the study. Source of funding This study was funded by Axon Animal Health. Portascope.com provided a videoendoscope free of charge for the purposes of this study. Acknowledgements The authors would like to thank Axon Animal Health and Portascope.com for their generous support of the project, the trainers for their cooperation and Ashleigh Dand and Arja Pöntinen for their assistance in performing the examinations. Authorship B.W. Sykes contributed to the study design, data collection, study execution, data analysis and interpretation, and preparation and approval of the manuscript. K.M. Sykes contributed to data collection, study execution and preparation and approval of the manuscript. G.D. Hallowell contributed to study design, data analysis and interpretation and preparation and approval of the manuscript. Equine Veterinary Journal 47 (215) EVJ Ltd 289
6 Comparison of 3 doses of omeprazole in EGUS treatment B. W. Sykes et al. Manufacturers addresses a Axon Animal Health, Belrose, New South Wales, Australia. b Portascope.com, Bradenton, Florida, USA. c Graphpad Software, La Jolla, California, USA. d SPSS Inc, Chicago, Illinois, USA. e f References 1. Andrews, F.M., Sifferman, R.L., Bernard, W., Hughes, F.E., Holste, J.E., Daurio, C.P., Alva, R. and Cox, J.L. (1999) Efficacy of omeprazole paste in the treatment and prevention of gastric ulcers in horses. Equine Vet. J. 31, Suppl. 29, Doucet, M.Y., Vrins, A.A., Dionne, R., Alva, R. and Ericsson, G. (23) Efficacy of a paste formulation of omeprazole for the treatment of naturally occurring gastric ulcers in training Standardbred racehorses in Canada. Can. Vet. J. 44, Lester, G.D., Smith, R.L. and Robertson, I.D. (25) Effects of treatment with omeprazole or ranitidine on gastric squamous ulceration in racing Thoroughbreds. J. Am. Vet. Med. Ass. 227, MacAllister, C.G., Sifferman, R.L., McClure, S.R., White, G.W., Vatistas, N.J., Holste, J.E., Ericsson, G. and Cox, J.L. (1999) Effects of omeprazole paste on healing of spontaneous gastric ulcers in horses and foals: a field trial. Equine Vet. J. 31, Suppl. 29, Murray, M.J., Haven, M.L., Eichorn, E.S., Zhang, D., Eagleson, J. and Hickey, G.J. (1997) Effects of omeprazole on healing of naturally-occurring gastric ulcers in Thoroughbred racehorses. Equine Vet. J. 29, Sykes, B.W., Sykes, K.M. and Hallowell, G.D. (213) A comparison of two doses of omeprazole in the treatment of EGUS: a blinded, randomised, clinical trial. Equine Vet. J. 46, Hepburn, R. (211) Gastric ulceration in horses. In Pract. 33, Jenkins, C.C., Frazier, D.L., Blackford, J.T., Andrews, F.M., Mattsson, H., Olovsson, S.-G. and McCleod, M. (1992) Pharmacokinetics and antisecretory effects of intravenous omeprazole in horses. Equine Vet. J. 24, Suppl. 13, Jenkins, C.C., Blackford, J.T., Andrews, F., Frazier, D.L., Mattsson, H., Olovsson, S.-G. and Peterson, A. (1992) Duration of antisecretory effects of oral omeprazole in horses with chronic gastric cannulae. Equine Vet. J. 24, Suppl. 13, Andrews, F. and Jenkins, C.C. (1992) Effect of oral omeprazole on basal and pentagastrin-stimulated gastric secretion in young female horses. Equine Vet. J. 24, Suppl. 13, Daurio, C.P., Holste, J.E., Andrews, F.M., Merritt, A.M., Blackford, J.T., Dolz, F. and Thompson, D.R. (1999) Effect of omeprazole paste on gastric acid secretion in horses. Equine Vet. J. 31, Sandin, A., Andrews, F.M., Nadeau, J.A., Doherty, T.J. and Nilsson, G. (1999) Effects of intramuscular omeprazole on gastric acid secretion in horses over a twenty-four hour period. Equine Vet. J. 31, Andrews, F.M., Frank, N., Sommardahl, C.S., Buchanan, B.R., Elliott, S.B. and Allen, V.A. (26) Effects of intravenously administrated omeprazole on gastric juice ph and gastric ulcer scores in adult horses. J. Vet. Int. Med. 2, Haven, M.L., Dave, K., Burrow, J.A., Merritt, A.M., Harris, D., Zhang, D. and Hickey, G.J. (1999) Comparison of the antisecretory effects of omeprazole when administered intravenously, as acid-stable granules and as an oral paste in horses. Equine Vet. J. 31, Merritt, A.M., Sanchez, L.C., Burrow, J.A., Church, M. and Ludzia, S. (23) Effect of GastroGard and three compounded oral omeprazole preparations on 24 h intragastric ph in gastrically cannulated mature horses. Equine Vet. J. 35, Lorenzo-Figueras, M. and Merritt, A. (22) Effects of exercise on gastric volume and ph in the proximal portion of the stomach of horses. Am. J. Vet. Res. 63, Merritt, A. (29) Appeal for proper usage of the term EGUS : equine gastric ulcer syndrome. Equine Vet. J. 41, Begg, L.M. and O Sullivan, C.B. (23) The prevalence and distribution of gastric ulceration in 345 racehorses. Aust. Vet. J. 81, Dionne, R., Vrins, A. and Doucet, M. (23) Gastric ulcers in Standardbred racehorses: prevalence, lesion description, and risk factors. J. Vet. Int. Med. 17, Luthersson, N., Nielsen, K.H., Harris, P. and Parkin, T.D.H. (29) The prevalence and anatomical distribution of equine gastric ulceration syndrome (EGUS) in 21 horses in Denmark. Equine Vet. J. 41, Luthersson, N., Nielsen, K.H., Harris, P. and Parkin, T.D.H. (29) Risk factors associated with equine gastric ulceration syndrome (EGUS) in 21 horses in Denmark. Equine Vet. J. 41, McClure, S.R., White, G.W., Sifferman, R.L., Bernard, W., Doucet, M.Y., Vrins, A., Holste, J.E., Fleishman, C., Alva, R. and Cramer, L.G. (25) Efficacy of omeprazole paste for prevention of gastric ulcers in horses in race training. J. Vet. Int. Med. 226, White, G., McClure, S. and Sifferman, R. (27) Effects of short-term light to heavy exercise on gastric ulcer development in horses and efficacy of omeprazole paste in preventing gastric ulceration. J. Am. Vet. Med. Ass. 23, Habershon-Butcher, J.L., Hallowell, G.D., Bowen, I.M. and Sykes, B.W. (212) Prevalence and risk factors for ulceration of the gastric glandular mucosa in Thoroughbred racehorses in training in the UK and Australia [Abstract]. J. Vet. Int. Med. 26, Murray, M.J., Nout, Y.S. and Ward, D.L. (21) Endoscopic findings of the gastric antrum and pylorus in horses: 162 cases (1996-2). J. Vet. Int. Med. 15, Andrews, F., Bernard, W., Byars, D., Cohen, N., Divers, T., MacAllister, C., McGladdery, A., Merritt, A., Murray, M., Orsini, J., Snyder, J. and Vatistas, N. (1999) Recommendations for the diagnosis and treatment of equine gastric ulcer syndrome (EGUS). Equine Vet. Educ. 11, Richards, N., Hinch, G.N. and Rowe, J.B. (26) The effect of current grain feeding practices on hindgut starch fermentation and acidosis in the Australian racing Thoroughbred. Aust. Vet. J. 84, Bermingham, E., del Castillo, J.R.E., Lainesse, C., Paloske, K. and Radecki, S. (212) Demonstrating bioequivalence using clinical endpoint studies. J. Vet. Pharmacol. Ther. 35, Lee, K.N., Lee, O.Y., Choi, M.G., Choi, S.R., Lee, D.H., Lee, Y.C., Kim, T.N., Choi, S.C., Rew, J.S. and Seol, S.Y. (211) Prevention of NSAID-associated gastroduodenal injury in healthy volunteers a randomized, double-blind, multicenter study comparing DA-961 with misoprostol. J. Korean Med. Sci. 26, Shin, J.M. and Sachs, G. (28) Pharmacology of proton pump inhibitors. Curr. Gastroenterol. Rep. 1, Al Jassim, R., McGowan, T., Andrews, F. and McGowan, C. (28) Gastric ulceration in horses: the role of bacteria and lactic acid; Australian Government: Rural Industries Research and Development Corporation, Kingston. pp Contreras, M., Morales, A., Garcia-Amado, M.A., De Vera, M., Bérmudez, V. and Gueneau, P. (27) Detection of Helicobacter-like DNA in the gastric mucosa of Thoroughbred horses. Lett. Appl. Microbiol. 45, Morales, A., Garcia, F. and Bermudez, V. (21) Detection of Helicobacter-like organisms in Thoroughbred horses from Venezuela. Braz. J. Vet. Path. 3, Fox, J. (22) The non-h. pylori helicobacters: their expanding role in gastrointestinal and systemic diseases. Gut 5, Husted, L., Jensen, T.K., Olsen, S.N. and Mølbak, L. (21) Examination of equine glandular stomach lesions for bacteria, including Helicobacter spp by fluorescence in situ hybridisation. BMC Microbiol. 1, Martineau, H., Thomson, H. and Taylor, D. (29) Pathology of gastritis and gastric ulceration in the horse. Part 1: range of lesions present in 21 mature individuals. Equine Vet. J. 41, Nadeau, J.A. and Andrews, F.M. (29) Equine gastric ulcer syndrome: the continuing conundrum. Equine Vet. J. 41, MacAllister, C.G., Morgan, S.J., Borne, A.T. and Pollet, R.A. (1993) Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses. J. Am. Vet. Med. Ass. 22, Andrews, F., Reinemeyer, C.R. and Longhofer, S.L. (29) Effects of top-dress formulations of suxibuzone and phenylbutazone on development of gastric ulcers in horses. Vet. Ther. 1, Equine Veterinary Journal 47 (215) EVJ Ltd
Preliminary investigations into a novel, long-acting, injectable, intramuscular formulation of omeprazole in the horse
Experimental and Basic Research Studies Preliminary investigations into a novel, long-acting, injectable, intramuscular formulation of omeprazole in the horse B. W. SYKES*, K. KATHAWALA, Y. SONG, S. GARG,
More informationEquine gastric squamous and glandular disease update
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Equine gastric squamous and glandular disease update Author : Gayle Hallowell Categories : Equine, Vets Date : July 3, 2017
More informationEquine Gastric Ulcer Syndrome
Equine Gastric Ulcer Syndrome Dr. Kaitlin McDonald, DVM Swiftsure Equine Veterinary Services presented in part with: Island Equine Veterinary Services & Eden Equine Veterinary Services The Plan Anatomy
More informationThe Effect of EGUSIN SLH and EGUSIN 250 on Reducing Gastric Ulcer Scores in Thoroughbred Horses Final Report April 12, 2011
The Effect of EGUSIN SLH and EGUSIN 250 on Reducing Gastric Ulcer Scores in Thoroughbred Horses Final Report April 12, 2011 Principal Investigator: Dr. Frank Andrews a Co-Principal Investigator: Dr. Nan
More informationThe Equine Stomach. by: Multiple Authors March , Article # 5068
The Equine Stomach by: Multiple Authors March 01 2004, Article # 5068 The Milne Lecture, named for AAEP past president and distinguished life member Frank J. Milne, each year honors a researcher for his
More informationEffects of Intravenously Administrated Omeprazole on Gastric Juice ph and Gastric Ulcer Scores in Adult Horses
J Vet Intern Med 2006;20:1202 1206 Effects of Intravenously Administrated Omeprazole on Gastric Juice ph and Gastric Ulcer s in Adult Horses Frank M. Andrews, Nicholas Frank, Carla S. Sommardahl, Benjamin
More informationGastric ulcers are highly prevalent in performance
J Vet Intern Med 2014;28:925 933 Efficacy of Omeprazole Powder Paste or Enteric-Coated Formulation in Healing of Gastric Ulcers in Horses K. Birkmann, H.K. Junge, E. Maischberger, M. Wehrli Eser, and C.C.
More informationProceedings of the 13th International Congress of the World Equine Veterinary Association WEVA
www.ivis.org Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA October 3-5, 2013 Budapest, Hungary Reprinted in IVIS with the Permission of the WEVA Organizers
More informationThe term Equine Gastric Ulcer Syndrome (EGUS)
ECEIM Consensus Statement J Vet Intern Med 2015;29:1288 1299 Consensus Statements of the European College of Equine Internal Medicine (ECEIM) provide veterinarians with guidelines regarding the pathophysiology,
More information- Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
MERIAL LTD. USA Product Label http://www.vetdepot.com 3239 SATELLITE BLVD., DULUTH, GA, 30096 Telephone: 888-637-4251 Website: www.merial.com GASTROGARD Merial (omeprazole) Oral Paste for Equine Ulcers
More informationGASTRIC ULCERATION. Gastroduodenoscopy This is the term for scoping the stomach and the duodenum.
GASTRIC ULCERATION Dr C.J. (Kate) Savage BVSc(Hons), MS, PhD, Diplomate ACVIM Specialist in Equine Internal Medicine Head, Clinical Services, Equine Centre, University of Melbourne, Werribee 3030, VIC,
More informationUlcers in the Stomach and Colon; Diagnosis and Treatment: A Pain in the Gut!
Published in IVIS with the permission of the AAEP Close this window to return to IVIS Ulcers in the Stomach and Colon; Diagnosis and Treatment: A Pain in the Gut! Frank M. Andrews, DVM, MS Author s Address:
More informationNew Maryland Racing Medication Guidelines
New Maryland Racing Medication Guidelines January 1, 2014 NEW MEDICATION REFORMS EFFECTIVE JANUARY 1, 2014 The Mid Atlantic racing states have joined together to implement a uniform medication and drug
More informationNSAIDs: the Past, Present, and Future
NSAIDs: the Past, Present, and Future Resident Seminar - November 2017 Lisanne Gallant, DVM Large Animal Medicine Resident Outline Physiology Review Use in Large Animals Adverse Effects Cases The Future
More informationSuitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)
STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.
More informationJust where it s needed.
Relief. Just where it s needed. Tissue-selective 7,8 Strong safety profile 5,6,10,11 For dogs and cats Onsior is available in a range of convenient and easy-to-dose formulations. Injectable solution for
More informationAcute Laminitis in the UK The Redwings Study
Acute Laminitis in the UK The Redwings Study Nicola Jarvis BVetMed Cert AVP(EM) MRCVS Redwings Horse Sanctuary Nine farms Over 1,300 resident horses, ponies, donkeys and mules Over 500 more in guardian
More informationFinal Report. Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014
Final Report Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014 PUBLISHED BY Meat & Livestock Australia Limited Locked Bag 991 NORTH SYDNEY NSW 2059
More informationWITHDRAWAL TIME RECOMMENDATIONS ARIZONA RACE TRACKS MEET
WITHDRAWAL TIME RECOMMENDATIONS ARIZONA RACE TRACKS 2018-19 MEET IMPORTANT WARNING: The information on drug withdrawal times does not constitute and is not a warranty, guarantee, assurance, undertaking,
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 October 2013 EMEA/CVMP/EWP/141272/2011 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in cattle
More informationMaryland Racing Commission Medication Guidelines
Maryland Racing Commission Medication Guidelines August 1, 2015 Maryland Racing Medication Guidelines The Mid Atlantic racing states have joined together to implement a uniform medication and drug testing
More informationTHE VETERINARIAN'S CHOICE. Compendium clinical Trials. Introducing new MILPRO. from Virbac. Go pro. Go MILPRO..
THE VETERINARIAN'S CHOICE. Introducing new MILPRO from Virbac. Compendium clinical Trials Go pro. Go MILPRO.. milbemycin/praziquantel Content INTRODUCTION 05 I. EFFICACY STUDIES IN CATS 06 I.I. Efficacy
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationRandlab Gastroscopy Standard Operating Procedure RANDLAB. Veterinary Medicines.
Randlab Gastroscopy Standard Operating Procedure Veterinary Medicines Gastroscopy Standard Operating Procedure Randlab Gastroscopy Standard Operating Procedure Randlab is keen to extend its leadership
More informationARCI Controlled Therapeutic Medication Schedule for Horses - Version 2.2 Revised April 2015
ARCI Schedule for Horses - Version 2.2 Revised April 2015 Acepromazine 10 nanograms per milliliter as 2-(1- hydroxyethyl) promazine sulfoxide (HEPS) in urine Single intravenous dose of acepromazine at
More informationchoice The Rilexine Palatable Tablets First generation cephalosporin for skin infections Now registered for ONCE daily administration*
Virbac Dermatology Palatable Tablets The choice First generation cephalosporin for skin infections Now registered for ONCE daily administration* are only available under Veterinary Authorisation. www.virbac.co.nz
More informationPeriod of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationCritical appraisal Randomised controlled trial questions
Critical appraisal Randomised controlled trial questions Korpivaara, M., Laapas, K., Huhtinen, M., Schoning, B., Overall, K. (2017) Dexmedetomidine oromucosal gel for noise-associated acute anxiety and
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationClinical trials conducted in subjects with naturally
Review J Vet Intern Med 2013 Evidence-Based Medicine: The Design and Interpretation of Noninferiority Clinical Trials in Veterinary Medicine K.J. Freise, T.-L. Lin, T.M. Fan, V. Recta, and T.P. Clark Noninferiority
More informationARCI Controlled Therapeutic Medication Schedule for Horses - Version 3.2 Revised December 9, 2016.
ARCI Schedule for Horses - Version 3.2 Revised December 9, 2016. Acepromazine 10 nanograms per milliliter as 2-(1- hydroxyethyl) promazine sulfoxide (HEPS) in urine Single intravenous dose of acepromazine
More informationSynopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets
Synopsis Name of the sponsor Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Name of active ingredient Title of the study Study
More informationARCI Controlled Therapeutic Medication Schedule for Horses - Version 4.1 Revised January, 2019
ARCI Schedule for Horses - Version 4.1 Revised January, 2019 Acepromazine 10 nanograms per milliliter as 2-(1- hydroxyethyl) promazine sulfoxide (HEPS) in urine Single intravenous dose of acepromazine
More informationReduce the risk of recurrence Clear bacterial infections fast and thoroughly
Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological
More informationMeloxicam vs etodolac cox 2 inhibition
Meloxicam vs etodolac cox 2 inhibition The Borg System is 100 % Meloxicam vs etodolac cox 2 inhibition of GI. Aspirin inhibits plt aggregration via inhibition of platelet COX. Meloxicam least. Etodolac
More informationPOST-OPERATIVE ANALGESIA AND FORMULARIES
POST-OPERATIVE ANALGESIA AND FORMULARIES An integral component of any animal protocol is the prevention or alleviation of pain or distress, such as that associated with surgical and other procedures. Pain
More informationThe Prevalence of NSAID related ulcer and Helicobacter pylori related ulcer in Hasan Sadikin General Hospital Bandung Indonesia.
The Prevalence of NSAID related ulcer and Helicobacter pylori related ulcer in Hasan Sadikin General Hospital Bandung Indonesia. Ali Djumhana *),Sujono Hadi*) and Makmuri Jusuf**) *)SubDivision Gastroenterohepatology
More informationTandan, Meera; Duane, Sinead; Vellinga, Akke.
Provided by the author(s) and NUI Galway in accordance with publisher policies. Please cite the published version when available. Title Do general practitioners prescribe more antimicrobials when the weekend
More informationFrank Zanzuccki, Executive Director. Calendar Reference: See Summary below for explanation of exception to calendar requirement.
LAW AND PUBLIC SAFETY NEW JERSEY RACING COMMISSION Horse Racing Medication and Testing Procedures Proposed Amendment: Authorized By: N.J.A.C. 13:70-14A.9 New Jersey Racing Commission, Frank Zanzuccki,
More informationThe world s first and only pour-on anti-inflammatory for cattle FAST PAIN RELIEF
The world s first and only pour-on anti-inflammatory for cattle FAST PAIN RELIEF NOTHING IS SIMPLER THAN POUR-ON RELIEF FOR PAIN, FEVER AND ACUTE INFLAMMATION easy to dose easy to apply easy on animals
More informationEsophago-gastroduodenal ulceration complicated by duodenal perforation in a three year old Thoroughbred colt: a case report
Esophago-gastroduodenal ulceration complicated by duodenal perforation in a three year old Thoroughbred colt: a case report B. Bezdekova Equine Clinic, University of Veterinary and Pharmaceutical Sciences,
More informationProceedings of the 56th Annual Convention of the American Association of Equine Practitioners - AAEP -
http://www.ivis.org Proceedings of the 56th Annual Convention of the American Association of Equine Practitioners - AAEP - December 4-8, 2010 Baltimore, Maryland, USA Next Meeting : Nov. 18-22, 2011 -
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationPyloric ulceration and stenosis in a two-year-old thoroughbred filly: a case report
Veterinarni Medicina, 51, 2006 (2): 75 80 Case Report Pyloric ulceration and stenosis in a two-year-old thoroughbred filly: a case report B. BEZDEKOVA, P. JAHN, J. MEZEROVA Equine Clinic, Faculty of Veterinary
More informationComparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle
Treatment Study DRAXXIN vs. Nuflor July 2005 Comparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle Pfizer Animal Health, New York,
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationDoug Carithers 1 William Russell Everett 2 Sheila Gross 3 Jordan Crawford 1
Comparative Efficacy of fipronil/(s)-methoprene-pyriproxyfen (FRONTLINE Gold) and Sarolaner (Simparica ) Against Induced Infestations of Ixodes scapularis on Dogs Doug Carithers 1 William Russell Everett
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationMeloxicam withdrawal time veterinarian bovine
Meloxicam withdrawal time veterinarian bovine The Borg System is 100 % Meloxicam withdrawal time veterinarian bovine Meloxicam Pain Relief in Cows and Calves. Meloxicam meat and milk withdrawal the standard
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 February 2016 CVMP/344/1999-Rev.2 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in Draft Draft
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationIrish Greyhound Board. Scientific Advisory Committee on Doping and Medication Control. Opinion on Carprofen
Irish Greyhound Board Scientific Advisory Committee on Doping and Medication Control Opinion on Carprofen The Committee has been examining the advice it would give the Board on the threshold for carprofen
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
19 January 2017 EMA/CVMP/344/1999-Rev.2 Committee for Medicinal products for Veterinary Use Guideline on the conduct of efficacy studies for intramammary products for use in cattle Draft agreed by Efficacy
More informationPain management: advances and possible complications
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Pain management: advances and possible complications Author : Celia Marr Categories : Equine, Vets Date : August 22, 2016
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NEFOTEK 100 mg/ml solution for injection for cattle, horses and pigs [AT, CZ, IE, PL, SK, UK, DE, FR, ES, HU, IT, SI] COXOFEN
More informationDr. Omar S. Tabbouche, M.Sc, D.Sc, Pharm.D Head of Pharmacy Department New Mazloum Hospital Tripoli, Lebanon
Efficacy & Safety of Ketoprofen 25mg vs. Paracetamol 1g intravenous preparations in the management of fever in adults: A pilot, double-blind, parallel-group, randomized controlled trial Dr. Omar S. Tabbouche,
More informationComparison of Lufenuron and Nitenpyram Versus Imidacloprid for Integrated Flea Control*
P. F. Miller, B. A. Peters, and C. A. Hort Comparison of Lufenuron and Nitenpyram Versus Imidacloprid for Integrated Flea Control* Peter F. Miller, MSc, PhD a Bryce A. Peters, B. App Sc a Colin A. Hort,
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationTreating Rosacea in the Era of Bacterial Resistance. This presentation is sponsored by Galderma Laboratories, L.P.
Treating Rosacea in the Era of Bacterial Resistance This presentation is sponsored by Galderma Laboratories, L.P. Lecture Discuss rosacea as an inflammatory condition Assess the psychosocial impact of
More informationThe Institutional Animal Care and Use Committee (IACUC) Aquatic Animals: Analgesia and Anesthesia formulary
The Institutional Animal Care and Use Committee (IACUC) Aquatic Animals: Analgesia and Anesthesia formulary The appropriate use of pain medications (analgesics) and anesthetics is a critical aspect of
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 20 mg/ml solution for injection for cattle, pigs and horses. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/389/98-FINAL July 1998 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS ENROFLOXACIN (extension to
More informationedition of the Association of Racing Commissioners International (ARCI s) Uniform Classifi cation Guidelines for Foreign Substances.
2016 STANDING RULE 35A MEDICATION AND DRUG RULES AND GUIDELINES The NCHA s Medication and Drug Rules and Guidelines ( Medication Rules ) have been put in place to protect and prolong the welfare and competitiveness
More informationWhich is More Effective in Altering the Intra-Gastric ph in Dogs, Omeprazole or Ranitidine?
Which is More Effective in Altering the Intra-Gastric ph in Dogs, Omeprazole or Ranitidine? A Knowledge Summary by Adam Swallow BVSc MRCVS 1* 1 University of Bristol, Senate House, Tyndall Ave, Bristol,
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/005/00-FINAL-Rev.1 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE TESTING
More informationMeloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration
Inflamm. res. 50, Supplement 1 (2001) S5 S9 1023-3830/01/01S5-05 $ 1.50+0.20/0 Birkhäuser Verlag, Basel, 2001 Inflammation Research Meloxicam: a review of its pharmacokinetics, efficacy and tolerability
More informationSUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationRESPONSIBILITIES OF THE PRESCRIBING VETERINARIAN
APPENDIX 15 AUSTRALIAN VETERINARY ASSOCIATION (AVA) CODE OF PRACTICE FOR PRESCRIPTION AND USE OF PRODUCTS WHICH CONTAIN ANTIMICROBIAL AGENTS [Adopted 7 May 2008] INTRODUCTION The purpose of this Code of
More informationNon-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without
May 2013 Contents About NSAIDs What about COXselectivity? How effective are NSAIDs? Adverse effects of NSAIDs How frequent are the adverse effects of NSAIDs? General prescribing guidelines for NSAIDs What
More informationOptimizing Antimicrobial Stewardship Activities Based on Institutional Resources
Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Andrew Hunter, PharmD, BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center Andrew.hunter@va.gov
More informationTransition cows have decreased immune function. The transition period. Inflammation, Immune Function, and the Transition Cow.
Overview Inflammation, Immune Function, and the Transition Cow Barry Bradford Kansas State University Herd Health & Nutrition Conferences April 2016 Immunity and inflammation in the transition cow Long
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection
More informationCritical appraisal Randomised controlled trial questions
Critical appraisal Randomised controlled trial questions Moreau et al. (2003) Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis Introduction
More informationStudy population The target population for the model were hospitalised patients with cellulitis.
Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals Vinken A G, Li J Z, Balan D A, Rittenhouse B E, Willke R J, Goodman C Record Status This is a
More informationScientific Discussion post-authorisation update for Rheumocam extension X/007
5 May 2011 EMA/170257/2011 Veterinary Medicines and Product Data Management Scientific Discussion post-authorisation update for Rheumocam extension X/007 Scope of extension: addition of 20 mg/ml solution
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AT, BE, BG, CY, CZ, DE, EE, EL, ES, FR, HR, HU, IE, IT, LT, LU, NL, PT, RO, SK, UK: Kelaprofen 100 mg/ml, solution for injection
More informationZOETIS INC. 333 PORTAGE STREET, KALAMAZOO, MI, Telephone: Customer Service: Website: EXCEDE FOR SWINE
ZOETIS INC. 333 PORTAGE STREET, KALAMAZOO, MI, 49007 Telephone: 269-359-4414 Customer Service: 888-963-8471 Website: www.zoetis.com Every effort has been made to ensure the accuracy of the information
More informationAcid suppression plays an important role in the management
J Vet Intern Med 2011;25:47 54 Efficacy of Oral Famotidine and 2 Omeprazole Formulations for the Control of Intragastric ph in Dogs K. Tolbert, S. Bissett, A. King, G. Davidson, M. Papich, E. Peters, and
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Helicobacter pylori testing and eradication in adults bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly
More informationGuidance Document. Veterinary Operating Instructions. Guidance re: Requirements for Authorising Veterinarians Notice.
Guidance Document Veterinary Operating Instructions Guidance re: Requirements for Authorising Veterinarians Notice 28 August 2015 A guidance document issued by the Ministry for Primary Industries Title
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox
More informationAustralian and New Zealand College of Veterinary Scientists. Membership Examination June Veterinary Pharmacology Paper 1
Australian and New Zealand College of Veterinary Scientists Membership Examination June 2012 Veterinary Pharmacology Paper 1 Perusal time: Fifteen (15) minutes Time allowed: Two (2) hours after perusal
More informationNSAIDs Are You Following the Rules?
NSAIDs Are You Following the Rules? As equestrians, we expect a lot from our performance horses. Sometimes pain and inflammation of their joints can happen right before a show or competition. Before administering
More informationCommonly Used Analgesics
Commonly Used Analgesics The following analgesics are intended for general use in the species of laboratory animals commonly used at NEOUCOM. The animals genetic background and other factors may have a
More informationAntibiotic Prophylaxis in Spinal Surgery Antibiotic Guidelines. Contents
Antibiotic Prophylaxis in Spinal Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): Authors Division: DCSS & Tertiary Medicine Unique
More informationANNEX III LABELLING AND PACKAGE LEAFLET
ANNEX III LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Card box and package leaflet for brown glass bottle (Type 1) 1. NAME OF THE
More informationINTRODUCTION TO WILDLIFE PHARMACOLOGY. Lisa Fosco Wildlife Rehabilitation Manager Toronto Wildlife Centre
INTRODUCTION TO WILDLIFE PHARMACOLOGY Lisa Fosco Wildlife Rehabilitation Manager Toronto Wildlife Centre General Pharmacology Factors That Affect Drug Absorption The dosage form Blood supply to the area
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 500 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,
More informationJ. vet. Pharmacol. Therap. doi: /jvp SHORT COMMUNICATION H. K. KNYCH*, S. D. STANLEY*, R. M. ARTHUR & D. S. MCKEMIE*
J. vet. Pharmacol. Therap. doi: 10.1111/jvp.12328. SHORT COMMUNICATION Disposition of the anti-ulcer medications ranitidine, cimetidine, and omeprazole following administration of multiple doses to exercised
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT COLICEN 4.000.000 UI/ml solution for use in drinking water/milk 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationIrish Medicines Board
Irish Medicines Board (Reference Member State) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Pestigon 50 mg Spot-On Solution for Cats Pestigon vet 50 mg
More informationNUMBER: /2005
Purpose PAGE 1 OF 7 The purpose of this policy is to describe the procedures for keeping and maintaining animal medical records. This procedure is approved by the Creighton University Institutional Animal
More informationPharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses
C. Boeckh, C. Buchanan, A. Boeckh, S. Wilkie, C. Davis, T. Buchanan, and D. Boothe Pharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses Christine Boeckh, DVM, MS a Charles
More informationMetacam. The Only NSAID Approved for Cats in the US. John G. Pantalo, VMD Professional Services Veterinarian. Think easy. Think cat. Think METACAM.
Metacam The Only NSAID Approved for Cats in the US John G. Pantalo, VMD Professional Services Veterinarian Think easy. Think cat. Think METACAM. Today s Agenda New pain management guidelines for cats Only
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12 1. NAME OF THE VETERINARY MEDICINAL PRODUCT HALOCUR 0.5 mg/ml oral solution for calves 2. Qualitative and quantitative composition Active substance Halofuginone
More information